Immunohistochemical Prognostic Markers of Esophageal Squamous Cell Carcinoma: a Systematic Review

Overview

Journal Chin J Cancer

Publisher Biomed Central

Specialty Oncology

Date 2017 Aug 19

PMID 28818096

Citations 39

Authors

Chunni Wang

Jingnan Wang

Zhaoli Chen

Yibo Gao

Jie He

Affiliations

Soon will be listed here.

Abstract

Background: Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy, with a high incidence and poor prognosis. In the past several decades, hundreds of proteins have been reported to be associated with the prognosis of ESCC, but none has been widely accepted to guide clinical care. This study aimed to identify proteins with great potential for predicting prognosis of ESCC.

Methods: We conducted a systematic review on immunohistochemical (IHC) prognostic markers of ESCC according to the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines. Literature related to IHC prognostic markers of ESCC were searched from PubMed, Embase, Web of Science, and Cochrane Library until January 30th, 2017. The risk of bias of these original studies was evaluated using the Quality in Prognosis Studies (QUIPS) tool.

Results: We identified 11 emerging IHC markers with reproducible results, including eight markers [epidermal growth factor receptor (EGFR), Cyclin D1, vascular endothelial growth factor (VEGF), Survivin, Podoplanin, Fascin, phosphorylated mammalian target of rapamycin (p-mTOR), and pyruvate kinase M2 (PKM2)] indicating unfavorable prognosis and 3 markers (P27, P16, and E-cadherin) indicating favorable prognosis of ESCC.

Conclusion: Strong evidence supports that these 11 emerging IHC markers or their combinations may be useful in predicting prognosis and aiding personalized therapy decision-making for ESCC patients.

Citing Articles

Association of NR0B1 with Malignant Phenotypes in Esophageal Squamous Cell Carcinoma Through Modulation of p53-Independent Cell-Cycle Regulation.

Iizuka A, Kanda M, Sato Y, Shimizu D, Umeda S, Tanaka H Ann Surg Oncol. 2025; .

PMID: 40080367 DOI: 10.1245/s10434-025-17109-y.

Enhances Cancer Cell Activities and Serves as a Prognosticator in Esophageal Squamous Cell Carcinoma.

Bayasgalan T, Kanda M, Sato Y, Zhu H, Hamrah M, Martinez F Cancer Genomics Proteomics. 2025; 22(2):306-325.

PMID: 39993802 PMC: 11880929. DOI: 10.21873/cgp.20503.

Integrating single-cell sequencing and machine learning to uncover the role of mitophagy in subtyping and prognosis of esophageal cancer.

Tian F, He X, Wang S, Liang Y, Wang Z, Hu M Apoptosis. 2025; .

PMID: 39948301 DOI: 10.1007/s10495-024-02061-1.

Hsa_circ_0001615 downregulation inhibits esophageal cancer development through miR-142-5p/β-catenin.

Dai Y, Xu Q, Xia M, Chen C, Xiong X, Yang X PeerJ. 2024; 12:e17089.

PMID: 38464761 PMC: 10921930. DOI: 10.7717/peerj.17089.

Mendelian Randomization Validates the Immune Landscape Mediated by Aggrephagy in Esophageal Squamous Cell Carcinoma Patients from the Perspectives of Multi-omics.

Yu H, Si G, Si F J Cancer. 2024; 15(7):1940-1953.

PMID: 38434988 PMC: 10905403. DOI: 10.7150/jca.93376.

References

Torzewski M, Sarbia M, Heep H, Dutkowski P, Willers R, Gabbert H . Expression of Bcl-X(L), an antiapoptotic member of the Bcl-2 family, in esophageal squamous cell carcinoma. Clin Cancer Res. 1998; 4(3):577-83. View

Chen M, Cai E, Huang J, Yu P, Li K . Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012; 21(7):1126-34. DOI: 10.1158/1055-9965.EPI-12-0020. View

Tong L, Yuan S, Feng F, Zhang H . Role of podoplanin expression in esophageal squamous cell carcinoma: a retrospective study. Dis Esophagus. 2011; 25(1):72-80. DOI: 10.1111/j.1442-2050.2011.01211.x. View

Sarbia M, Bittinger F, Grabellus F, Verreet P, Dutkowski P, Willers R . Expression of Bax, a pro-apoptotic member of the Bcl-2 family, in esophageal squamous cell carcinoma. Int J Cancer. 1997; 73(4):508-13. DOI: 10.1002/(sici)1097-0215(19971114)73:4<508::aid-ijc9>3.0.co;2-3. View

Mao Y, He J, Gao S, Xue Q . [Controversies in the surgical treatment for esophageal carcinoma and future investigation]. Zhonghua Wei Chang Wai Ke Za Zhi. 2015; 18(9):851-4. View

Fujiwara S, Noguchi T, Takeno S, Kimura Y, Fumoto S, Kawahara K . Hypermethylation of p16 gene promoter correlates with loss of p16 expression that results in poorer prognosis in esophageal squamous cell carcinomas. Dis Esophagus. 2008; 21(2):125-31. DOI: 10.1111/j.1442-2050.2007.00735.x. View

Hou X, Wei J, Fu J, Wang X, Luo R, He J . Vascular Endothelial Growth Factor is a Useful Predictor of Postoperative Distant Metastasis and Survival Prognosis in Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2015; 22(11):3666-73. DOI: 10.1245/s10434-015-4390-x. View

Chen W, Zheng R, Zeng H, Zhang S . The incidence and mortality of major cancers in China, 2012. Chin J Cancer. 2016; 35(1):73. PMC: 4971631. DOI: 10.1186/s40880-016-0137-8. View

Zhao Q, Shen J, Shen Z, Wu Z, Xu X, Xie J . Phosphorylation of fascin decreases the risk of poor survival in patients with esophageal squamous cell carcinoma. J Histochem Cytochem. 2010; 58(11):979-88. PMC: 2958140. DOI: 10.1369/jhc.2010.955765. View

10.

Nam T, Lee J, Cho S, Chung I, Ahn S, Song J . Low hMLH1 expression prior to definitive chemoradiotherapy predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Lett. 2007; 260(1-2):109-17. DOI: 10.1016/j.canlet.2007.10.026. View

11.

Chang M, Lee H, Lee B, Kim Y, Lee J, Kim W . Differential protein expression between esophageal squamous cell carcinoma and dysplasia, and prognostic significance of protein markers. Pathol Res Pract. 2005; 201(6):417-25. DOI: 10.1016/j.prp.2005.04.005. View

12.

Lin Y, Wu M, Li D, Wu X, Zheng R . Prognostic and clinicopathological features of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin and cyclin D1 expression in human esophageal squamous cell carcinoma. World J Gastroenterol. 2004; 10(22):3235-9. PMC: 4572286. DOI: 10.3748/wjg.v10.i22.3235. View

13.

Ikeguchi M, Oka S, Gomyo Y, Tsujitani S, Maeta M, Kaibara N . Combined analysis of p53 and retinoblastoma protein expressions in esophageal cancer. Ann Thorac Surg. 2000; 70(3):913-7. DOI: 10.1016/s0003-4975(00)01719-7. View

14.

Takikita M, Hu N, Shou J, Wang Q, Giffen C, Taylor P . Biomarkers of apoptosis and survival in esophageal squamous cell carcinoma. BMC Cancer. 2009; 9:310. PMC: 2745431. DOI: 10.1186/1471-2407-9-310. View

15.

Mathew R, Arora S, Khanna R, Mathur M, Shukla N, Ralhan R . Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. Eur J Cancer. 2002; 38(6):832-41. DOI: 10.1016/s0959-8049(02)00007-2. View

16.

Xia H, Chen S, Huang H, Ma H . Survivin over-expression is correlated with a poor prognosis in esophageal cancer patients. Clin Chim Acta. 2015; 446:82-5. DOI: 10.1016/j.cca.2015.04.009. View

17.

Kurabayashi A, Furihata M, Matsumoto M, Ohtsuki Y, Sasaguri S, Ogoshi S . Expression of Bax and apoptosis-related proteins in human esophageal squamous cell carcinoma including dysplasia. Mod Pathol. 2001; 14(8):741-7. DOI: 10.1038/modpathol.3880383. View

18.

Qu H, Zhao L, Zhan S, Geng C, Xu L, Xin Y . Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis. J Thorac Dis. 2017; 8(11):3197-3204. PMC: 5179395. DOI: 10.21037/jtd.2016.11.01. View

19.

Setoyama T, Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Yokomakura N . alpha-catenin is a significant prognostic factor than E-cadherin in esophageal squamous cell carcinoma. J Surg Oncol. 2007; 95(2):148-55. DOI: 10.1002/jso.20610. View

20.

Zhao X, Li H, Chen H, Liu Y, Zhang L, Liu S . Expression of e-cadherin and beta-catenin in human esophageal squamous cell carcinoma: relationships with prognosis. World J Gastroenterol. 2003; 9(2):225-32. PMC: 4611316. DOI: 10.3748/wjg.v9.i2.225. View